Novartis COVID-19 Trials

Novartis clinical trial efforts in COVID-19 R&D.

Content from this campaign

Research & Reports

Novartis to Sponsor Large Clinical Trial of Hydroxychloroquine in Hospitalized COVID-19 Patients

Monday, April 20, 2020 - 10:30

Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease.

More from Novartis

Novartis Foundation Leprosy Elimination Initiative

The Novartis Foundation is convening experts from the global health and anti-leprosy community to discuss the current state of leprosy treatment and...

The Novartis Malaria Initiative

For over a decade, the Novartis Malaria Initiative has been a pioneer in the fight against malaria. Focused on access, treatment, R&D and capacity...

Novartis – science based innovation for better patient outcomes

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

Novartis Access: Medicines to treat chronic diseases in lower-income countries

Novartis recently announced the launch of the Novartis Access Portfolio, a first-of-its-kind portfolio approach in healthcare industry, aiming to...

Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US

Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on...

Novartis US Foundation

Initiatives summarizing efforts from the Novartis US Foundation.

Novartis COVID-19 Trials

Novartis clinical trial efforts in COVID-19 R&D.

Novartis US Foundation COVID-19 Response

In response to the COVID-19 pandemic in the US, the Novartis US Foundation established a Response Fund, which will provide USD 5 million over a one...